COMT and pancreatic neoplasm: These conflicting results suggest that NB responds differently to COMT inhibition compared to colorectal or pancreatic cancer, which may be attributed to the high expression of DA—eliciting the release of ROS when highly overexpressed—in NB compared to other malignancies 4, 5.